Related Experiment Video

Updated: May 25, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease

Sarkis Morales-Vidal1, Michael J Schneck, Murray Flaster

  • 1Department of Neurology, Stroke Program, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153, USA. smoralesvidal@lumc.edu

Expert Review of Neurotherapeutics
|February 1, 2012
PubMed

Insights

Novel anticoagulants like dabigatran, rivaroxaban, and apixaban offer alternatives for stroke prevention in nonvalvular atrial fibrillation patients. These drugs aim to reduce the risk of recurrent ischemic strokes, a major global health concern.

Area of Science:

  • Cardiovascular Medicine
  • Neurology
  • Pharmacology

Background:

  • Stroke is a significant cause of death and disability globally, with ischemic strokes accounting for the majority of cases.
  • Nonvalvular atrial fibrillation increases the risk of stroke due to potential clot formation.
  • Traditional antithrombotic therapies have limitations, necessitating alternative strategies.

Purpose of the Study:

  • To review the role of novel oral anticoagulants (NOACs) in preventing stroke.
  • To evaluate dabigatran, rivaroxaban, and apixaban for stroke prevention in nonvalvular atrial fibrillation (NVAF) patients.
  • To discuss NOACs as an alternative antithrombotic intervention for ischemic cerebrovascular disease.

Main Methods:

  • Review of existing literature and clinical trial data on dabigatran, rivaroxaban, and apixaban.
  • Analysis of efficacy and safety profiles of these novel anticoagulants in NVAF populations.
  • Comparison of novel anticoagulants with traditional therapies for stroke prevention.

Main Results:

  • Novel anticoagulants demonstrate significant efficacy in reducing stroke risk in patients with NVAF.
  • Specific agents like dabigatran, rivaroxaban, and apixaban offer comparable or superior outcomes to warfarin in certain patient groups.
  • Safety profiles, including bleeding risks, are crucial considerations for clinical application.

Conclusions:

  • Novel anticoagulants represent a valuable therapeutic option for stroke prevention in patients with nonvalvular atrial fibrillation.
  • Dabigatran, rivaroxaban, and apixaban provide effective antithrombotic intervention, potentially improving patient outcomes.
  • Further research and individualized patient selection are essential for optimal use of these agents.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...